DC Funds, LP reported 2 positions worth $829.48K for the quarter ended Jun 30, 2026, down 26.0% on the prior quarter. It opened 0 new positions, added to 0, trimmed 0 and exited 0. Its largest holding is TScan Therapeutics, Inc. at 74.4% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
No positions were reduced this quarter.
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | TCRX TScan Therapeutics, Inc. | Healthcare | 630.0K | $617.46K | 74.44% | 0 | 0.0% | Unchanged | 0.48% |
| 2 | HOWL Werewolf Therapeutics, Inc. | Healthcare | 589.1K | $212.02K | 25.56% | 0 | 0.0% | Unchanged | 1.21% |
Tip. Select a row to see that position’s full history at DC Funds.
As of its Q2 2026 13F filing, DC Funds, LP’s five largest positions were TScan Therapeutics, Inc. (TCRX) at 74.4%, Werewolf Therapeutics, Inc. (HOWL) at 25.6% of the reported portfolio.
DC Funds, LP reported a 13F portfolio worth $829.48K across 2 positions for Q2 2026. That is down 26.0% from the previous quarter.
From the Form 13F-HR reports DC Funds, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.